Highlights
- 1Nature communications · 2020
- 2Nature communications · 2024
- 3The Journal of clinical investigation · 2021
Publications
138 publications
Funding
26 grantsView NIH portfolio on RePORTER ↗
Active
8 grants- MPIR01CA301637-02The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancerNational Cancer Institute · 2025–2030
- PIR01CA297829-02Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancerNational Cancer Institute · 2025–2030
- MPIR01CA287724-02Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancerNational Cancer Institute · 2024–2029
- Co-IR37CA282407-01A1ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancerNational Cancer Institute · 2024–2029
- KP1614289The role of SPOP mutation in opposing lineage plasticity in neuroendocrine prostate cancerAmerican Urological Association · 2026–2028
- Co-IR01CA272466-01A1"Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis"National Cancer Institute · 2023–2028
- Sub-PI5 U01C A257638-04Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate CancerNational Cancer Institute · 2021–2027 · via Case Western Reserve University
- Sub-PIPCF 20YOUN09Prostate Cancer Foundation subaward for Janny Villa PulgarinProstate Cancer Foundation · 2023–2027 · via The General Hospital Corporation (dba Massachusetts General Hospital)
Completed grants (18)
- Sub-PIW81XWH2210363BPTF-mediated gene regulation in prostate cancerU.S. Department of Defense · 2022–2025 · via University of Maryland, BaltimoreNo publications yet
- MPIUCF 234555-01Immune Microenvironment in Orthotopic Models of Prostate Cancer in Immunocompetent MiceUrology Care Foundation · 2024–2025
- Co-IHT9425-24-1-0310Characterizing 3'-UTR biology as a mechanism of therapy response in high risk prostate cancer.U.S. Department of Defense · 2024–2025
- PIR01CA233650-05Collaborative genomic alterations and transcriptional control in prostate cancerNational Cancer Institute · 2019–2025
- PIR37CA215040-07Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate CancerNational Cancer Institute · 2018–2025
- Co-IPCF 227920-01Targeting lipid metabolism and diet in patients with locally advanced prostate cancerProstate Cancer Foundation · 2023–2023
- Co-IR01CA221152-01A1G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate TumorigenesisNational Cancer Institute · 2018–2023
- Co-IP50CA211024-05Weill Cornell Medicine (WCM) SPORE in Prostate CancerNational Cancer Institute · 2017–2023
- PIAddgene 705468Addgene 705468Addgene, Inc. · 2022–2023
- PIAddgene 703836Addgene 703836Addgene, Inc. · 2022–2023
- PIW81XWH-19-1-0403Defining the Potential of Early Molecular Subtypes of Prostate Cancer to Progress to AR-Indifferent DiseaseU.S. Department of Defense · 2019–2022
- PI88C-16Subtype-specific modes of clinical and molecular progression in prostate cancerDamon Runyon Cancer Research Foundation · 2019–2022
- KPPCF 17091418-01The Role of CHD1 Loss on Cistrome Reprogramming and Prostate Cancer ProgressionProstate Cancer Foundation · 2017–2021
- PIW81XWH-17-1-0385Coordinated Roles of SPOP Mutation and CHD1 Deletion in Prostate Cancer PathogenesisU.S. Department of Defense · 2017–2019Fellowship
- MPIUCF 180747-01Repurposing drugs for prostatic disease, a high-throughput imaging based approachAmerican Urological Association · 2018–2019
- PI88-16Presurgical Trials to Target Distinct Subclasses of Localized Prostate CancerDamon Runyon Cancer Research Foundation · 2016–2019
- PIK08CA187417-05Genomic Instability and DNA Repair in a Distinct Molecular Class of Prostate CancerNational Cancer Institute · 2014–2019Career
- PIPCF 15060870-03 EWOFTargeting Genomic Instability in SPOP Mutant Prostate Cancer.Prostate Cancer Foundation · 2014–2017
Honors & distinctions
2 honors
- Member · American Society for Clinical Investigation · 2020
- Damon Runyon Fellowship / Grant · Damon Runyon Cancer Research Foundation · 2016
Available technologies
1 technologyView full WCM portfolio ↗
News mentions
3 mentionsView all WCM news ↗
- Prostate Cancer Foundation Awards Grants to Weill Cornell Medicine InvestigatorsMarch 26, 2026
Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation.
- Putting the Brakes on Prostate Cancer CellsDecember 13, 2024
Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.
- Innovative Model Provides Valuable Insights into Prostate Cancer SpreadSeptember 23, 2024
A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.
Mentoring
6 menteesAll publications with mentees →
- JOJude OwireduCell & Developmental Biology (PhD)
- KAKaveri AroraPostdoc mentee · 2017–2019
- HCHarsha ChoudharyPostdoc mentee · 2021–2023
- AKAndrea KomljenovicPostdoc mentee · 2021–2022
- IGIvana GrbesaPostdoc mentee · 2021–2021
- DNDrexel NeumannMD mentee · Class of 2019
External relationships
Advisory/Scientific Board Member
American Urological Association
Professional Services
American Urological Association
Other Interest
National Cancer Institute · United States Department of Defense
Other
Pfizer, Inc.